Eric Tsao, founder of Synermore Biologics, talks about how a company employing 90 people can successfully operate internationally and efficiently progress with its biosimilar and innovative product development pipeline. He also discusses what business strategy and potential partnerships will determine the successful growth of the company in the future.
You have a successful track record working at well-known biotech companies such as Medimmune and in non-profit sectors (Aeras). What market opportunity did you identify back in 2013 to found Synermore Biologics?
"It is not very common to run a biotech company of our size - currently we employ 90 experts capable of running the operations across the world."
